Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic development financing agreement with Gilead Sciences. The financing agreement will provide up to $210 million in funding to support select clinical studies of ...

Related Keywords

New York , United States , United Kingdom , London , City Of , , Steering Committee , Gilead Sciences , Launch Therapeutics , Joint Steering Committee ,